Nicholas D Klemen, M.D.
National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nicholas D Klemen, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:42 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06690281 · A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal MalignanciesNational Cancer Institute (NCI) · withdrawn · Gastrointestinal Carcinoma, Pancreatic Cancer, Hepatocellular Cancer · principal investigator
- Ph2NCT06410534 · A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal CancerNational Cancer Institute (NCI) · withdrawn · Colorectal Cancer, Gastroesophageal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in pancreatic cancer.